Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized Patients: Risk factors and outcomes

Journal of Association of Physicians of India

Volumn 57, Issue 9, 2009, Pages

  Shanthi, M ^a   Sekar, Uma ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ARTICLE; CROSS INFECTION; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; METABOLISM; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; BETA-LACTAMASES; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 70349525333     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50: 43-8
2. Harris A, Torreß-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999;28:1128-33
3. Hemalatha V, Sekar U, Kamat V. Detection of metallo betalactamases producing Pseudomonas aeruginosa in hospitalized patients. Indian J Med Res 2005;122:148-152
4. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-ß-Lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18: 306-325
5. Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. Detection of Pseudomonas aeruginosa producing metallo-slactamases in a large centralized laboratory. J Clin Microbiol 2005;43: 3129-35
6. Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation of metalloß- lactamase- producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2002;40: 3798-3801
7. Fritsche TR, Sader HS, Toleman MA, Walsh TR, Jones RN. Emerging metallo-ß-lactamase-mediated resistances: A summary report from the worldwide SENTR Y antimicrobial surveillance program. Clin Infect Dis 2005; 41 Suppl 4:S276-8
8. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002;34:340-5
9. Wang CY, Jerng JS, Cheng KY, Lee LN, Yu CJ, Hsueh PR et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect 2006; 12: 63-68
10. Fortaleza CM, Freire MP, Filho Dde C, de Carvalho Ramos M. Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol 2006; 27:901-6
11. Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW, Woo JH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004;48: 224-28
12. Clinical Laboratory Standard Institute.2007. Performance standards for antimicrobial susceptibility testing;Seventeenth informational supplement M100-S17,16th ed., Clinical Laboratory Standard Institute, Wayne, PA.
13. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk Synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2003; 41: 4623-9
14. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29
15. Appleman MD, Belzberg H, Citron DN, Heseltine PN, Yellin AE, Murray J, and Berne TV. Invitro activities of nontraditional antimicrobials against Multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob agents chemother 2000; 44: 1035-1040
16. R ossolini GM and Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11 (Suppl. 4): 17-32
17. Falagas ME and Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Critical Care 2006, 10:R27
18. Harris AD, McGregor JC, Furuno JP. What infection control interventions should be undertaken to control multidrug-resistant Gram-negative bacteria?. Clin Infect Dis 2006; 43 Suppl 2:S57-61